{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:40:55Z","timestamp":1793756455535,"version":"4.6.1"},"reference-count":138,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,7,17]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing and progressive interstitial lung disease of unknown aetiology with a pathogenesis still partly unknown. Several microvascular and macrovascular abnormalities have been demonstrated in the pathogenesis of IPF and related pulmonary hypertension (PH), a complication of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We carried out a non-systematic, narrative literature review aimed at describing the role of the vasculature in the natural history of IPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The main molecular pathogenetic mechanisms involving vasculature (\n                      <jats:italic>i.e.<\/jats:italic>\n                      endothelial-to-mesenchymal transition, vascular remodelling, endothelial permeability, occult alveolar haemorrhage, vasoconstriction and hypoxia) and the genetic basis of vascular remodelling are described. The prevalence and clinical relevance of associated PH are highlighted with focus on the vasculature as a prognostic marker. The vascular effects of current antifibrotic therapies, the role of pulmonary vasodilators in the treatment of disease, and new pharmacological options with vascular-targeted activity are described.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The vasculature plays a key role in the natural history of IPF from the early phases of disease until development of PH in a subgroup of patients, a complication related to a worse prognosis. Pulmonary vascular volume has emerged as a novel computed tomography finding and a predictor of mortality, independent of PH. New pharmacological options with concomitant vascular-directed activity might be promising in the treatment of IPF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.00550-2024","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T11:55:26Z","timestamp":1730980526000},"page":"00550-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Vascular involvement in idiopathic pulmonary fibrosis"],"prefix":"10.1183","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9672-3534","authenticated-orcid":false,"given":"Michele","family":"Mondoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-5298","authenticated-orcid":false,"given":"Rocco","family":"Rinaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Ryerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8548-6019","authenticated-orcid":false,"given":"Cristina","family":"Albrici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Baccelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Tirelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Cefalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5104-7437","authenticated-orcid":false,"given":"Giulia","family":"Nalesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1806-0430","authenticated-orcid":false,"given":"Giulia","family":"Ferranti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausta","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1600-4474","authenticated-orcid":false,"given":"Giovanni","family":"Sotgiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Guazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Centanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"2025011303501348000_10.6.00550-2024.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2025011303501348000_10.6.00550-2024.2","doi-asserted-by":"crossref","first-page":"17074","DOI":"10.1038\/nrdp.2017.74","article-title":"Idiopathic pulmonary fibrosis","volume":"3","author":"Martinez","year":"2017","journal-title":"Nat Rev Dis Primer"},{"key":"2025011303501348000_10.6.00550-2024.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201006-0894CI"},{"key":"2025011303501348000_10.6.00550-2024.4","first-page":"25","article-title":"Observational, multicenter study on the efficacy, tolerability, and safety of nintedanib in patients with idiopathic pulmonary fibrosis older than 80 years","volume":"102","author":"Mondoni","year":"2023","journal-title":"Respir Int Rev Thorac Dis"},{"key":"2025011303501348000_10.6.00550-2024.5","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-018-0730-2"},{"key":"2025011303501348000_10.6.00550-2024.6","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcu012"},{"key":"2025011303501348000_10.6.00550-2024.7","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1152\/ajpcell.00097.2023","article-title":"The endothelium in lung fibrosis: a core signalling hub in disease pathogenesis?","volume":"325","author":"Flie\u00dfer","year":"2023","journal-title":"Am J Physiol Cell Physiol"},{"key":"2025011303501348000_10.6.00550-2024.8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2213-2600(16)30222-3","article-title":"Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities","volume":"5","author":"King","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2025011303501348000_10.6.00550-2024.9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00543-3"},{"key":"2025011303501348000_10.6.00550-2024.10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12931-020-01570-2","article-title":"Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights","volume":"21","author":"Ruffenach","year":"2020","journal-title":"Respir Res"},{"key":"2025011303501348000_10.6.00550-2024.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02316-2014"},{"key":"2025011303501348000_10.6.00550-2024.12","first-page":"288","article-title":"Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis","volume":"76","author":"Nathan","year":"2008","journal-title":"Respir Int Rev Thorac Dis"},{"key":"2025011303501348000_10.6.00550-2024.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01537-2014"},{"key":"2025011303501348000_10.6.00550-2024.14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022"},{"key":"2025011303501348000_10.6.00550-2024.15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.chest.2022.02.012","article-title":"Screening strategies for pulmonary hypertension in patients with interstitial lung disease: a multidisciplinary Delphi study","volume":"162","author":"Rahaghi","year":"2022","journal-title":"Chest"},{"key":"2025011303501348000_10.6.00550-2024.16","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01711-1"},{"key":"2025011303501348000_10.6.00550-2024.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2007.05.012"},{"key":"2025011303501348000_10.6.00550-2024.18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ccm.2019.02.011","article-title":"Exercise pathophysiology in interstitial lung disease","volume":"40","author":"Molgat-Seon","year":"2019","journal-title":"Clin Chest Med"},{"key":"2025011303501348000_10.6.00550-2024.19","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0355-2020"},{"key":"2025011303501348000_10.6.00550-2024.20","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-3357"},{"key":"2025011303501348000_10.6.00550-2024.21","first-page":"407","article-title":"Distinguishing pulmonary hypertension in interstitial lung disease by ventilation and perfusion defects measured by cardiopulmonary exercise testing","volume":"86","author":"Armstrong","year":"2013","journal-title":"Respir Int Rev Thorac Dis"},{"key":"2025011303501348000_10.6.00550-2024.22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/resp.12306","article-title":"Impact of pulmonary hypertension on exercise performance in patients with interstitial lung disease undergoing evaluation for lung transplantation","volume":"19","author":"Armstrong","year":"2014","journal-title":"Respirol Carlton Vic"},{"key":"2025011303501348000_10.6.00550-2024.23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1440-1843.2010.01909.x","article-title":"Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension","volume":"16","author":"Boutou","year":"2011","journal-title":"Respirol Carlton Vic"},{"key":"2025011303501348000_10.6.00550-2024.24","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.healun.2023.11.005","article-title":"Derivation and validation of a noninvasive prediction tool to identify pulmonary hypertension in patients with IPF: evolution of the model FORD","volume":"43","author":"Nathan","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"2025011303501348000_10.6.00550-2024.25","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00571-2021"},{"key":"2025011303501348000_10.6.00550-2024.26","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00487-2022"},{"key":"2025011303501348000_10.6.00550-2024.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-020-03693-7"},{"key":"2025011303501348000_10.6.00550-2024.28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1237"},{"key":"2025011303501348000_10.6.00550-2024.29","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-02241-0"},{"key":"2025011303501348000_10.6.00550-2024.30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12964-023-01040-4","article-title":"Endothelial cell-derived MMP19 promotes pulmonary fibrosis by inducing E(nd)MT and monocyte infiltration","volume":"21","author":"Zhao","year":"2023","journal-title":"Cell Commun Signal"},{"key":"2025011303501348000_10.6.00550-2024.31","doi-asserted-by":"publisher","DOI":"10.1136\/thx.18.3.225"},{"key":"2025011303501348000_10.6.00550-2024.32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200308-1111OC"},{"key":"2025011303501348000_10.6.00550-2024.33","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200202-135OC"},{"key":"2025011303501348000_10.6.00550-2024.34","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2010-0365TR"},{"key":"2025011303501348000_10.6.00550-2024.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2006.02.026"},{"key":"2025011303501348000_10.6.00550-2024.36","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.4049\/jimmunol.159.3.1437","article-title":"The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis","volume":"159","author":"Keane","year":"1997","journal-title":"J Immunol"},{"key":"2025011303501348000_10.6.00550-2024.37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200608-1153CC"},{"key":"2025011303501348000_10.6.00550-2024.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2006.06.007"},{"key":"2025011303501348000_10.6.00550-2024.39","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-004-2542-z"},{"key":"2025011303501348000_10.6.00550-2024.40","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00060708"},{"key":"2025011303501348000_10.6.00550-2024.41","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3390\/biomedicines11061728","article-title":"The role of sphingolipids in regulating vascular permeability in idiopathic pulmonary fibrosis","volume":"11","author":"Jayant","year":"2023","journal-title":"Biomedicines"},{"key":"2025011303501348000_10.6.00550-2024.42","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/17476348.2020.1795832","article-title":"Endothelial to mesenchymal transition (EndMT) and vascular remodelling in pulmonary hypertension and idiopathic pulmonary fibrosis","volume":"14","author":"Gaikwad","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"2025011303501348000_10.6.00550-2024.43","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02345-2016"},{"key":"2025011303501348000_10.6.00550-2024.44","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-11-37"},{"key":"2025011303501348000_10.6.00550-2024.45","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00104814"},{"key":"2025011303501348000_10.6.00550-2024.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2013.12.002"},{"key":"2025011303501348000_10.6.00550-2024.47","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210728"},{"key":"2025011303501348000_10.6.00550-2024.48","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-018-0728-9"},{"key":"2025011303501348000_10.6.00550-2024.49","doi-asserted-by":"crossref","first-page":"e013310","DOI":"10.1161\/JAHA.119.013310","article-title":"Hypoxic pulmonary vasoconstriction and the diffusing capacity in pulmonary hypertension secondary to idiopathic pulmonary fibrosis","volume":"8","author":"Sakao","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2025011303501348000_10.6.00550-2024.50","doi-asserted-by":"publisher","DOI":"10.1063\/1.341220"},{"key":"2025011303501348000_10.6.00550-2024.51","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-3261fje"},{"key":"2025011303501348000_10.6.00550-2024.52","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/apha.12749","article-title":"The principal pathways involved in the in vivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension","volume":"219","author":"Kylhammar","year":"2017","journal-title":"Acta Physiol"},{"key":"2025011303501348000_10.6.00550-2024.53","doi-asserted-by":"crossref","first-page":"C882","DOI":"10.1152\/ajpcell.1992.262.4.C882","article-title":"Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction","volume":"262","author":"Post","year":"1992","journal-title":"Am J Physiol"},{"key":"2025011303501348000_10.6.00550-2024.54","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.38.2.99"},{"key":"2025011303501348000_10.6.00550-2024.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.09.001"},{"key":"2025011303501348000_10.6.00550-2024.56","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-0449"},{"key":"2025011303501348000_10.6.00550-2024.57","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/diagnostics12123107","article-title":"The genetic and epigenetic footprint in idiopathic pulmonary fibrosis and familial pulmonary fibrosis: a state-of-the-art review","volume":"12","author":"Tirelli","year":"2022","journal-title":"Diagnostics"},{"key":"2025011303501348000_10.6.00550-2024.58","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200601-012TK"},{"key":"2025011303501348000_10.6.00550-2024.59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050093"},{"key":"2025011303501348000_10.6.00550-2024.60","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00272-2022"},{"key":"2025011303501348000_10.6.00550-2024.61","doi-asserted-by":"crossref","first-page":"1430350","DOI":"10.1155\/2017\/1430350","article-title":"Pulmonary hypertension associated with idiopathic pulmonary fibrosis: current and future perspectives","volume":"2017","author":"Collum","year":"2017","journal-title":"Can Respir J"},{"key":"2025011303501348000_10.6.00550-2024.62","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M706797200"},{"key":"2025011303501348000_10.6.00550-2024.63","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-4-200802190-00006"},{"key":"2025011303501348000_10.6.00550-2024.64","doi-asserted-by":"crossref","first-page":"7265487","DOI":"10.1155\/2020\/7265487","article-title":"Novel molecular mechanisms of pulmonary hypertension: a search for biomarkers and novel drug targets-from bench to bed site","volume":"2020","author":"Gajecki","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"2025011303501348000_10.6.00550-2024.65","doi-asserted-by":"publisher","DOI":"10.1513\/pats.201002-024AW"},{"key":"2025011303501348000_10.6.00550-2024.66","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012513-104706"},{"key":"2025011303501348000_10.6.00550-2024.67","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00163.2007"},{"key":"2025011303501348000_10.6.00550-2024.68","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.108.182014"},{"key":"2025011303501348000_10.6.00550-2024.69","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00142.2016"},{"key":"2025011303501348000_10.6.00550-2024.70","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01483-2021"},{"key":"2025011303501348000_10.6.00550-2024.71","doi-asserted-by":"crossref","first-page":"e12311","DOI":"10.1002\/pul2.12311","article-title":"Pulmonary vascular dysfunction without pulmonary hypertension: a distinct phenotype in idiopathic pulmonary fibrosis","volume":"14","author":"Nathan","year":"2024","journal-title":"Pulm Circ"},{"key":"2025011303501348000_10.6.00550-2024.72","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijcard.2018.04.053","article-title":"Use of TAPSE\/PASP ratio in pulmonary arterial hypertension: an easy shortcut in a congested road","volume":"266","author":"Guazzi","year":"2018","journal-title":"Int J Cardiol"},{"key":"2025011303501348000_10.6.00550-2024.73","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.chest.2018.11.015","article-title":"Right ventricular functional reserve in early-stage idiopathic pulmonary fibrosis: an exercise two-dimensional speckle tracking Doppler echocardiography study","volume":"155","author":"D'Andrea","year":"2019","journal-title":"Chest"},{"key":"2025011303501348000_10.6.00550-2024.74","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.3390\/jcm11206115","article-title":"Non-invasive assessment of right ventricle to arterial coupling for prognosis stratification of fibrotic interstitial lung diseases","volume":"11","author":"Santoro","year":"2022","journal-title":"J Clin Med"},{"key":"2025011303501348000_10.6.00550-2024.75","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/resp.13485","article-title":"Quantitative CT-derived vessel metrics in idiopathic pulmonary fibrosis: a structure-function study","volume":"24","author":"Jacob","year":"2019","journal-title":"Respirol Carlton Vic"},{"key":"2025011303501348000_10.6.00550-2024.76","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02524-2016"},{"key":"2025011303501348000_10.6.00550-2024.77","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12880-022-00803-8","article-title":"Pulmonary vascular volume is associated with DLCO and fibrotic score in idiopathic pulmonary fibrosis: an observational study","volume":"22","author":"Wu","year":"2022","journal-title":"BMC Med Imaging"},{"key":"2025011303501348000_10.6.00550-2024.78","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-214375"},{"key":"2025011303501348000_10.6.00550-2024.79","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02058-2021"},{"key":"2025011303501348000_10.6.00550-2024.80","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216382"},{"key":"2025011303501348000_10.6.00550-2024.81","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2025011303501348000_10.6.00550-2024.82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2025011303501348000_10.6.00550-2024.83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2025011303501348000_10.6.00550-2024.84","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00228-020-02947-4","article-title":"The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?","volume":"76","author":"Ferrara","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2025011303501348000_10.6.00550-2024.85","doi-asserted-by":"crossref","first-page":"102464","DOI":"10.1016\/j.jaut.2020.102464","article-title":"Pirfenidone alleviates lipopolysaccharide-induced lung injury by accentuating BAP31 regulation of ER stress and mitochondrial injury","volume":"112","author":"Du","year":"2020","journal-title":"J Autoimmun"},{"key":"2025011303501348000_10.6.00550-2024.86","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01758-2"},{"key":"2025011303501348000_10.6.00550-2024.87","doi-asserted-by":"crossref","first-page":"804327","DOI":"10.3389\/fphar.2021.804327","article-title":"Biphasic effect of pirfenidone on angiogenesis","volume":"12","author":"Gan","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025011303501348000_10.6.00550-2024.88","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12101"},{"key":"2025011303501348000_10.6.00550-2024.89","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.molimm.2018.05.003","article-title":"Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation","volume":"99","author":"Li","year":"2018","journal-title":"Mol Immunol"},{"key":"2025011303501348000_10.6.00550-2024.90","doi-asserted-by":"crossref","first-page":"284","DOI":"10.14336\/AD.2021.0617","article-title":"Pharmacological blockade of NLRP3 Inflammasome\/IL-1\u03b2-positive loop mitigates endothelial cell senescence and dysfunction","volume":"13","author":"Romero","year":"2022","journal-title":"Aging Dis"},{"key":"2025011303501348000_10.6.00550-2024.91","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00174914"},{"key":"2025011303501348000_10.6.00550-2024.92","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00766-0"},{"key":"2025011303501348000_10.6.00550-2024.93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158193"},{"key":"2025011303501348000_10.6.00550-2024.94","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10456-017-9543-z","article-title":"Effects of nintedanib on the microvascular architecture in a lung fibrosis model","volume":"20","author":"Ackermann","year":"2017","journal-title":"Angiogenesis"},{"key":"2025011303501348000_10.6.00550-2024.95","doi-asserted-by":"crossref","first-page":"101941","DOI":"10.1016\/j.pupt.2020.101941","article-title":"Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study","volume":"64","author":"Landi","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"2025011303501348000_10.6.00550-2024.96","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/cvr\/cvy186","article-title":"Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension","volume":"115","author":"Rol","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2025011303501348000_10.6.00550-2024.97","doi-asserted-by":"crossref","first-page":"e12178","DOI":"10.1002\/pul2.12178","article-title":"Pulmonary hypertension in interstitial lung disease: clinical trial design and end-points: a consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension","volume":"12","author":"Nathan","year":"2022","journal-title":"Pulm Circ"},{"key":"2025011303501348000_10.6.00550-2024.98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002110"},{"key":"2025011303501348000_10.6.00550-2024.99","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.chest.2020.02.016","article-title":"A randomized, double-blind, placebo-controlled study of pulsed, inhaled nitric oxide in subjects at risk of pulmonary hypertension associated with pulmonary fibrosis","volume":"158","author":"Nathan","year":"2020","journal-title":"Chest"},{"key":"2025011303501348000_10.6.00550-2024.100","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa1811737","article-title":"Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis","volume":"379","author":"Kolb","year":"2018","journal-title":"N Engl J Med"},{"key":"2025011303501348000_10.6.00550-2024.101","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025011303501348000_10.6.00550-2024.102","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-9-201305070-00003"},{"key":"2025011303501348000_10.6.00550-2024.103","doi-asserted-by":"crossref","first-page":"633A","DOI":"10.1378\/chest.132.4_MeetingAbstracts.633a","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis","volume":"132","author":"Krowka","year":"2007","journal-title":"Chest"},{"key":"2025011303501348000_10.6.00550-2024.104","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201403-0446OC"},{"key":"2025011303501348000_10.6.00550-2024.105","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1513\/AnnalsATS.202107-864OC","article-title":"A Phase-2 exploratory randomized controlled trial of INOpulse in patients with fibrotic interstitial lung disease requiring oxygen","volume":"19","author":"King","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2025011303501348000_10.6.00550-2024.106","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201011-1874OC"},{"key":"2025011303501348000_10.6.00550-2024.107","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00104612"},{"key":"2025011303501348000_10.6.00550-2024.108","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2213-2600(20)30356-8","article-title":"Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025011303501348000_10.6.00550-2024.109","doi-asserted-by":"crossref","first-page":"2045894020957234","DOI":"10.1177\/2045894020957234","article-title":"Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension","volume":"10","author":"Hemnes","year":"2020","journal-title":"Pulm Circ"},{"key":"2025011303501348000_10.6.00550-2024.110","doi-asserted-by":"crossref","first-page":"e12271","DOI":"10.1002\/pul2.12271","article-title":"Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension","volume":"13","author":"Caccamo","year":"2023","journal-title":"Pulm Circ"},{"key":"2025011303501348000_10.6.00550-2024.111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008470"},{"key":"2025011303501348000_10.6.00550-2024.112","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S2213-2600(21)00165-X","article-title":"Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study","volume":"9","author":"Nathan","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025011303501348000_10.6.00550-2024.113","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1007\/s12325-022-02229-8","article-title":"The antifibrotic effects of inhaled treprostinil: an emerging option for ILD","volume":"39","author":"Kolb","year":"2022","journal-title":"Adv Ther"},{"key":"2025011303501348000_10.6.00550-2024.114","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001310"},{"key":"2025011303501348000_10.6.00550-2024.115","doi-asserted-by":"crossref","first-page":"744826","DOI":"10.3389\/fphar.2021.744826","article-title":"Anlotinib inhibits PFKFB3-driven glycolysis in myofibroblasts to reverse pulmonary fibrosis","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025011303501348000_10.6.00550-2024.116","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/jphp.13183","article-title":"Anlotinib attenuated bleomycin-induced pulmonary fibrosis via the TGF-\u03b21 signalling pathway","volume":"72","author":"Ruan","year":"2020","journal-title":"J Pharm Pharmacol"},{"key":"2025011303501348000_10.6.00550-2024.117","doi-asserted-by":"publisher","DOI":"10.1038\/nm1685"},{"key":"2025011303501348000_10.6.00550-2024.118","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2021-001026"},{"key":"2025011303501348000_10.6.00550-2024.119","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.2147\/DDDT.S415453","article-title":"Inhibition of LPA-LPAR1 and VEGF-VEGFR2 signaling in IPF treatment","volume":"17","author":"Luo","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"2025011303501348000_10.6.00550-2024.120","doi-asserted-by":"publisher","DOI":"10.1513\/pats.201201-005AW"},{"key":"2025011303501348000_10.6.00550-2024.121","doi-asserted-by":"crossref","first-page":"A126","DOI":"10.1016\/j.chest.2023.07.136","article-title":"Pharmacokinects study to evaluate drug-drug interactions (DDI) between hzn-825 and pirfenidone\/nintedanib","volume":"164","author":"Song","year":"2023","journal-title":"Chest"},{"key":"2025011303501348000_10.6.00550-2024.122","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000208"},{"key":"2025011303501348000_10.6.00550-2024.123","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13044"},{"key":"2025011303501348000_10.6.00550-2024.124","unstructured":"Vicore pharma. Buloxibutid (C21) \u2013 IPF. Date last accessed: 3 September 2024. Date last updated 2023. https:\/\/vicorepharma.com\/our-programs\/rare-lung-diseases\/c21-ipf-fibrosis\/"},{"key":"2025011303501348000_10.6.00550-2024.125","doi-asserted-by":"crossref","first-page":"L258","DOI":"10.1152\/ajplung.00165.2021","article-title":"Coagulation factor-XII induces interleukin-6 by primary lung fibroblasts: a role in idiopathic pulmonary fibrosis?","volume":"322","author":"Jaffar","year":"2022","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2025011303501348000_10.6.00550-2024.126","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/cts.13180","article-title":"A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab","volume":"15","author":"McKenzie","year":"2022","journal-title":"Clin Transl Sci"},{"key":"2025011303501348000_10.6.00550-2024.127","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3892\/mmr.2023.13079","article-title":"Inhibition of TP signalling promotes endometriosis growth and neovascularization","volume":"28","author":"Furue","year":"2023","journal-title":"Mol Med Rep"},{"key":"2025011303501348000_10.6.00550-2024.128","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1164\/rccm.202106-1503OC","article-title":"Thromboxane-prostanoid receptor signaling drives persistent fibroblast activation in pulmonary fibrosis","volume":"206","author":"Suzuki","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025011303501348000_10.6.00550-2024.129","unstructured":"CR Pharma. A safety, tolerability, and pharmacokinetic study of NIP292 in healthy normal subjects. Date last accessed: 3 September 2023. Date last updated: 24 March 2023. https:\/\/clinicaltrials.gov\/study\/NCT04720443"},{"key":"2025011303501348000_10.6.00550-2024.130","doi-asserted-by":"crossref","first-page":"dmm049029","DOI":"10.1242\/dmm.049029","article-title":"Suppressing STAT3 activity protects the endothelial barrier from VEGF-mediated vascular permeability","volume":"14","author":"Wang","year":"2021","journal-title":"Dis Model Mech"},{"key":"2025011303501348000_10.6.00550-2024.131","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.2.9810008"},{"key":"2025011303501348000_10.6.00550-2024.132","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-7-200204020-00008"},{"key":"2025011303501348000_10.6.00550-2024.133","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2009.04.002"},{"key":"2025011303501348000_10.6.00550-2024.134","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/j.1440-1843.2010.01860.x","article-title":"The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease","volume":"15","author":"Corte","year":"2010","journal-title":"Respirol Carlton Vic"},{"key":"2025011303501348000_10.6.00550-2024.135","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00213911"},{"key":"2025011303501348000_10.6.00550-2024.136","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-204150"},{"key":"2025011303501348000_10.6.00550-2024.137","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/resp.12294","article-title":"Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors","volume":"19","author":"Zimmermann","year":"2014","journal-title":"Respirol Carlton Vic"},{"key":"2025011303501348000_10.6.00550-2024.138","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/resp.14378","article-title":"Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: a Bayesian retrospective observational cohort study","volume":"28","author":"Dawes","year":"2023","journal-title":"Respirology"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00550-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:40:44Z","timestamp":1740357644000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00550-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":138,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,11,25]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1183\/23120541.00550-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00550-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}